FDA Approves Gazyva for Primary Membranous Nephropathy
The approval marks the first drug cleared specifically for treating adults with this rare kidney disease.
Updated on Nov. 13, 2026 in Cancer

The FDA approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy, a rare kidney disease. Gazyva is the first drug approved specifically for this condition.
Why it matters
Before this approval, Gazyva had been cleared for certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome, but no drug had been approved specifically for primary membranous nephropathy. The decision gives adults with the disease a treatment option designed for their condition.
In the Phase 3 MAJESTY study of 142 adults over 104 weeks, 36% of patients receiving Gazyva achieved complete remission of proteinuria compared with 6% of those receiving tacrolimus. The extraction does not report outcomes beyond the 104-week study window.
The players
Gazyva (obinutuzumab)
Gazyva is an injectable antibody therapy previously approved for certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.
The details
Patients in the MAJESTY study were randomly assigned to receive either Gazyva or tacrolimus. Complete remission was defined as a urine protein-creatinine ratio of no more than 0.3 g/g with a stable estimated glomerular filtration rate at week 104, without rescue therapy, treatment failure, or early discontinuation. Gazyva's label carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Timeline
Week 104: Primary endpoint assessment of complete remission in the MAJESTY study.
November 13, 2026: FDA approval of Gazyva for primary membranous nephropathy is announced.
Health Landscape
This approval extends Gazyva's earlier kidney-related label expansions into lupus nephritis and childhood-onset idiopathic nephrotic syndrome, now reaching primary membranous nephropathy. Primary membranous nephropathy is caused by immune system attack on the glomeruli, and the approval adds a targeted option to a disease previously lacking one.
Adults diagnosed with primary membranous nephropathy now have an FDA-approved drug designed for their condition rather than relying solely on drugs approved for other diseases. Patients considering Gazyva should review its boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy with their clinicians.
The takeaway
Targeted antibody therapies are moving beyond cancer and into rare autoimmune kidney diseases, offering options where few existed. Patients should weigh the drug's boxed warnings against the trial's remission results when discussing treatment with their doctors.
Further reading
Explore more cancer treatment news to see how targeted antibody therapies are expanding into non-cancer conditions.






